Who is suitable for ChondroFiller injection in the hip

'Bone on bone' is one of the most commonly misapplied reasons for ruling out cartilage treatment — and for ChondroFiller injection in the hip, it is not an automatic disqualifier. Candidacy spans a genuinely broad spectrum: from focal, Grade III or IV cartilage defects with intact surrounding borders, through to diffuse Kellgren-Lawrence Grade III or IV osteoarthritis, including presentations that have already been described to patients as end-stage.

The critical threshold is not joint space width on a plain X-ray but whether any cartilage tissue remains. Provided some residual matrix is present — even in a heavily worn joint — the injectable collagen scaffold has biological material to work with and anchor to. There is no published upper age limit on the injection pathway.

Rather than applying a single grade cut-off, suitability is mapped across four clinical lenses. The mechanics lens examines how load is distributed across the joint and whether alignment supports repair. The chemistry lens evaluates intra-articular inflammation: a joint in a sustained inflammatory flare — with synovial thickening or elevated joint fluid — presents a less hospitable environment for scaffold integration than a calmer one. The biology lens considers the patient's innate tissue-repair capacity, which governs how vigorously host stem cells migrate into and populate the scaffold. The timing lens asks where the disease sits in its trajectory and whether the biological window for meaningful intervention is still open.

Before any treatment is offered, MRI or open MRI is reviewed at consultation to map the defect size and the quality of surrounding cartilage — this imaging review is the gateway step, not a self-assessment checklist.

Why ChondroFiller works differently from other cartilage treatments

Unlike surgical cartilage procedures that require a clean, prepared defect base, ChondroFiller injection works by addition rather than removal — a distinction that shapes everything about how it is delivered.

The product is a liquid at the point of injection. Once inside the joint, it self-gels within minutes, conforming to worn bone ends and forming a stable, porous collagen matrix across the damaged surface. The scaffold itself contains no donor cells; its role is to create the right physical environment for the body's own repair. Stem cells from the surrounding tissue migrate into the matrix, gradually differentiating into chondrocyte-like cells. As this process continues, the collagen resorbs and is progressively replaced by fibrocartilage-like repair tissue — matrix-induced chondrogenesis driven entirely by the patient's own biology.

Because the scaffold coats rather than fills a surgically excavated cavity, no debridement of the defect base is needed. That is what makes ultrasound-guided placement in an outpatient clinic mechanically feasible: the collagen can be deposited accurately into a fluid joint environment without operating-theatre conditions.

One brief distinction is worth noting here: Arthrosamid, a polyacrylamide hydrogel, targets the synovium and has no regenerative function — a separate mechanism covered in the context of combination protocols later in this article.

What the procedure involves

The appointment itself is straightforward compared with the surgical procedures patients may have already read about. On arrival at the outpatient clinic, local anaesthetic is administered to the hip area — there is no general anaesthetic, no operating theatre, and no overnight admission. The whole visit typically takes 30–45 minutes from start to discharge, with intravenous antibiotic cover administered as standard during the procedure.

Once the skin and deeper tissues are numb, the treating clinician positions an ultrasound probe over the hip to visualise the joint in real time. Guided by live imaging, 2.3 mL of ChondroFiller is deposited directly onto the load-bearing bone surfaces where the cartilage damage lies — placed accurately into the fluid joint environment without any need for surgical preparation of the defect. For patients with a larger worn area or disease affecting more than one compartment, two or three boxes may be used to ensure adequate coverage across the full surface; this reflects the extent of the defect rather than any increase in procedural complexity.

ChondroFiller is a CE-marked Class III medical device manufactured by Meidrix Biomedicals GmbH in Germany — the same regulatory category as implantable devices, which requires robust safety and performance data before clinical use is permitted.

Recovery, rehabilitation, and what the evidence shows

The most immediate practical constraint after a ChondroFiller injection is weight-bearing restriction. For 4–6 weeks post-injection, the hip is kept under protected loading — reduced-impact activity rather than complete immobility — to allow the collagen scaffold time to stabilise and begin cellular infiltration. Most patients manage this period with a temporary adjustment to daily routine.

Repair tissue takes considerably longer to register than a mechanical intervention would. Stem cell migration, chondrocyte differentiation, and early fibrocartilage deposition unfold over a 3–6 month window; MRI at that stage typically shows the first clear evidence of new tissue, not the finished result. Symptom change before this period should not be anticipated, and comparing progress at six weeks with a corticosteroid injection timetable misframes what the scaffold is doing.

Published hip outcome data report Harris Hip Score improvements of approximately 33 points in studied populations, including patients with focal cartilage defects and femoroacetabular impingement (FAI). Because the Harris Hip Score runs from 0 to 100, a gain of 33 points represents roughly the distance between severe and moderate-to-mild functional impairment — a shift that meets widely used thresholds for clinical significance. MOCART scores, which grade repair tissue quality on MRI from 0 to 100, have ranged from 70 to 87 across joint applications, indicating good-to-excellent structural fill. More than 19,000 procedures have been performed globally; the knee forms the largest cohort, and the hip evidence, while clinically meaningful, sits within that broader series rather than as a standalone large-scale trial — a point explored further in the evidence overview below.

For patients who respond well, a biennial top-up programme is available as a long-term joint-preservation strategy — something to consider at follow-up rather than at the point of first treatment.

When ChondroFiller injection is combined with other pathways

Treatment selection does not stop at a single injection for every hip presentation. Where Kellgren-Lawrence Grade III or IV osteoarthritis has created both cartilage loss at the bone ends and a compromised synovial environment, a dual-injection protocol combines ChondroFiller (2.3 mL deposited at the articular surfaces) with Arthrosamid (6 mL placed at the synovium). The two products address different targets within the same joint: ChondroFiller provides the regenerative scaffold for tissue repair, while Arthrosamid functions as a hydrogel cushion at the synovial lining — distinct mechanisms rather than a blended approach.

For the most structurally challenged presentations — sometimes referred to as 'impossible joint' cases — a Tri-Active protocol adds autologous mesenchymal stem cells to amplify the biological repair response alongside both injectables.

When cartilage loss is too extensive or structurally complex for any injection pathway to address adequately, Liquid Cartilage™ Surgery moves treatment into a single-stage arthroscopic setting. Here, ChondroFiller scaffold is co-delivered with patient-derived cells under direct joint visualisation — a step up in intervention level, but still within a single procedure.

Which tier is appropriate is determined by MRI defect mapping and full clinical assessment, not by patient preference or defect grade alone.

Contraindications, evidence limits, and how to find out if you qualify

Two contraindications are absolute: active intra-articular infection, which precludes any injectable joint procedure, and complete cartilage loss where no residual tissue remains to anchor the scaffold. Patients whose primary goal is rapid pain relief comparable to a corticosteroid injection are also poorly matched — biological repair builds over months, not days.

The hip evidence base merits honest acknowledgement. Published outcome data include manufacturer-sponsored investigations alongside independent clinical studies, and the hip cohort is narrower than the knee literature on which ChondroFiller's evidence profile is most mature. No head-to-head randomised controlled trial comparing in-clinic injection with arthroscopic scaffold delivery specifically in the hip has been identified — a meaningful gap to weigh in shared decision-making. Outcomes also vary by defect size, the quality of cartilage bordering the lesion, and individual biology, which is why standardised MRI review is mandatory before the procedure is offered rather than at the referral stage.

For referring GPs and physiotherapists, the patients most suited to imaging-guided hip scaffold assessment are those with MRI-confirmed partial- or full-thickness focal defects, or diffuse osteoarthritis with some residual cartilage, who have not responded adequately to conservative management.

Final candidacy rests on whether the full clinical picture — joint mechanics, inflammatory state, repair biology, and disease trajectory — supports scaffold integration. That assessment, including imaging review, is available through Professor Paul Y. F. Lee's team at londoncartilage.com. For the right patient, ChondroFiller injection represents a substantive alternative to the surgical pathways that have historically defined cartilage treatment in the hip.